{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bolus+Administered",
    "query": {
      "intervention": "Bolus Administered"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 715,
    "total_pages": 72,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bolus+Administered&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T10:01:12.350Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02268825",
      "title": "Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced GI Cancer"
      ],
      "interventions": [
        {
          "name": "MK-3475",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2015-01-23",
      "completion_date": "2017-06-26",
      "has_results": false,
      "last_update_posted_date": "2018-11-13",
      "last_synced_at": "2026-09-03T10:01:12.350Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02268825"
    },
    {
      "nct_id": "NCT00787176",
      "title": "The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pregnancy",
        "Labor Pain"
      ],
      "interventions": [
        {
          "name": "Group A Intravenous bolus of 1000 ml lactated ringers solution",
          "type": "DRUG"
        },
        {
          "name": "Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate",
          "type": "DRUG"
        },
        {
          "name": "Group C 125 mL/hr of lactated ringers",
          "type": "DRUG"
        },
        {
          "name": "Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 251,
      "start_date": "2007-09",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2022-01-13",
      "last_synced_at": "2026-09-03T10:01:12.350Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00787176"
    },
    {
      "nct_id": "NCT04605991",
      "title": "A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "LY900014",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 187,
      "start_date": "2020-11-04",
      "completion_date": "2022-02-04",
      "has_results": true,
      "last_update_posted_date": "2023-03-03",
      "last_synced_at": "2026-09-03T10:01:12.350Z",
      "location_count": 30,
      "location_summary": "Concord, California • Escondido, California • Fresno, California + 25 more",
      "locations": [
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04605991"
    },
    {
      "nct_id": "NCT00868660",
      "title": "Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Inflammatory Bowel Disease"
      ],
      "interventions": [
        {
          "name": "ZP1848",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zealand Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 66,
      "start_date": "2009-01",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2010-11-02",
      "last_synced_at": "2026-09-03T10:01:12.350Z",
      "location_count": 1,
      "location_summary": "Willingboro, New Jersey",
      "locations": [
        {
          "city": "Willingboro",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00868660"
    },
    {
      "nct_id": "NCT07349810",
      "title": "Post Operative Infusion Pump Pain Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Post Operative Pain"
      ],
      "interventions": [
        {
          "name": "Bupivacaine 0.5% Injectable Solution",
          "type": "DRUG"
        },
        {
          "name": "Ropivacaine 0.2% Injectable Solution",
          "type": "DRUG"
        },
        {
          "name": "1.3% liposomal bupivacaine (Exparel)",
          "type": "DRUG"
        },
        {
          "name": "ambIT Infusion Pump",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2026-01-01",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-09-03T10:01:12.350Z",
      "location_count": 1,
      "location_summary": "Somerset, New Jersey",
      "locations": [
        {
          "city": "Somerset",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07349810"
    },
    {
      "nct_id": "NCT00611897",
      "title": "N-acetylcysteine and NMDA Antagonist Interactions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cognitive Dysfunction"
      ],
      "interventions": [
        {
          "name": "N-acetylcysteine and ketamine",
          "type": "DRUG"
        },
        {
          "name": "placebo and ketamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "21 Years to 45 Years"
      },
      "enrollment_count": 16,
      "start_date": "2006-01",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2015-05-08",
      "last_synced_at": "2026-09-03T10:01:12.350Z",
      "location_count": 1,
      "location_summary": "West Haven, Connecticut",
      "locations": [
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00611897"
    },
    {
      "nct_id": "NCT00073593",
      "title": "Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cardiac Surgery",
        "Coronary Artery Bypass Surgery"
      ],
      "interventions": [
        {
          "name": "Bivalirudin",
          "type": "DRUG"
        },
        {
          "name": "Heparin",
          "type": "DRUG"
        },
        {
          "name": "Protamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Medicines Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2003-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-11-10",
      "last_synced_at": "2026-09-03T10:01:12.350Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00073593"
    },
    {
      "nct_id": "NCT01479465",
      "title": "Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Simtuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to match SIM",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 266,
      "start_date": "2011-12",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2019-04-17",
      "last_synced_at": "2026-09-03T10:01:12.350Z",
      "location_count": 56,
      "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Alhambra, California + 49 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01479465"
    },
    {
      "nct_id": "NCT06780111",
      "title": "Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "I-DXd",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Levoleucovorin",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil (5-FU)",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Sacituzumab tirumotecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rescue Medication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 298,
      "start_date": "2025-07-30",
      "completion_date": "2032-01-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-09-03T10:01:12.350Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06780111"
    },
    {
      "nct_id": "NCT01218867",
      "title": "CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Metastatic Melanoma",
        "Renal Cancer"
      ],
      "interventions": [
        {
          "name": "Anti-VEGFR2 CAR CD8 plus PBL",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 24,
      "start_date": "2010-11-10",
      "completion_date": "2015-12-15",
      "has_results": true,
      "last_update_posted_date": "2019-12-10",
      "last_synced_at": "2026-09-03T10:01:12.350Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01218867"
    }
  ]
}